Great f.y.i. Get hooked here!
Local, national & international business news and events.
OLDWICK, N.J.–(BUSINESS WIRE)–AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of “a” of First American Title Insurance Company (Omaha, NE) and its title subsidiaries, which are referred to as First
TINTON FALLS, N.J.–(BUSINESS WIRE)–#acquisitions–World Insurance Associates LLC (WIA), a Top 100 Insurance Agency, announced today that it acquired Fairways Insurance, Inc. (“Fairways”) of Cinnaminson, NJ on November 1, 2020. Terms of the transaction were not disclosed. Fairways is a full-service insurance agency
Bet Section Delivers Suite of New Personalized Betting Features, Further Deepening theScore’s Industry-Leading Media and Gaming Integrations TORONTO–(BUSINESS WIRE)–$SCR #sportsbetting—Score Media and Gaming Inc. (TSX: SCR) (“theScore” or the “Company”) today debuted Bet Section, its most integrated and personalized suite of betting
• Metagenomi is a genomic medicines company pioneering precision gene editing systems to advance curative therapies for oncology and genetic diseases • Proprietary and wholly owned gene editing platform offers the potential to expand the range of treatable diseases and to improve patient
Results for our CD19-targeted CAR T cell therapy lisocabtagene maraleucel (liso-cel) in patients with heavily pretreated mantle cell lymphoma and relapsed/refractory chronic lymphocytic leukemia Data showcasing BCMA-targeted CAR T cell therapy idecabtagene vicleucel (ide-cel), including updated results from the Phase 1 CRB-401
The U.S. 150-day delinquency rate reached its highest level since at least January 1999 Forbearance provisions have helped foreclosure rates maintain historic lows IRVINE, Calif.–(BUSINESS WIRE)–#Foreclosure–CoreLogic® (NYSE: CLGX), a leading global property information, analytics and data-enabled solutions provider, today released its monthly
LENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus Sunitinib Results of Investigational Phase 3 KEYNOTE-581/CLEAR Trial (Study 307) to be Presented at Upcoming Medical Meeting KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK): KEYTRUDA®
Deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases, showed significantly greater ACR 20 responses compared to placebo at 16 weeks and met all key secondary endpoints Deucravacitinib was well-tolerated with
JetBlue Adds 25 Additional Flights from the New York Area to Florida, California, and Top VFR Markets in the Caribbean Over Peak Thanksgiving Travel Dates NEW YORK–(BUSINESS WIRE)–JetBlue (NASDAQ: JBLU) today announced it is expanding service from New York City over the